Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Clinical pharmacology and therapeutics - 1 Jan 2002

Yasar Umit, Forslund-Bergengren Cecilia, Tybring Gunnel, Dorado Pedro, Llerena Adrián, Sjöqvist Folke, Eliasson Erik, Dahl Marja-Liisa

Abstract excerpt

BACKGROUND AND AIM: Losartan is metabolized by polymorphic CYP2C9 to E-3174. Our aim was to evaluate the pharmacokinetics of losartan and E-3174 in relation to the CYP2C9 genotype. METHODS: A 50-mg oral dose of losartan was given to 22 Swedish volunteers with different CYP2C9 genotypes. Losartan and E-3174 were analyzed by HPLC in plasma and urine samples collected up to 24 hours after drug intake. Furthermore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Cytochrome P-450 CYP2C9

Share to Losartan

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Share to Tetrazoles

Source

Identifiers

PMID: 11823761
DOI: 10.1067/mcp.2002.121216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.PMID 11823761Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.Semantic proximity Read ↗

[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].Semantic proximity Read ↗

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.Semantic proximity Read ↗

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

CYP2C9 genetic variants and losartan oxidation in a Turkish population.Semantic proximity Read ↗

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.Semantic proximity Read ↗

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.Semantic proximity Read ↗

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.Semantic proximity Read ↗

Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects.Semantic proximity Read ↗

Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.